Cereno Scientific obtains additional patent protection for Phase II drug candidate CS1 in Japan
Cereno Scientific (XSAT: CRNO B) today announced strengthening of intellectual property rights (IPR) for drug candidate CS1 in the major market Japan. The patent is part of the third patent family which now has protection in Russia as well as Japan. It adds to the growing IPR portfolio for CS1 covering almost all global markets.
“The expansion of CS1’s patent protection in Japan is an important step in our efforts to protect our innovations and strengthen the commercial positioning of the drug candidate. Japan is one of the largest pharmaceutical markets in the world and it is therefore key to have a strong IPR position in the market”, says Sten R. Sörensen, CEO at Cereno Scientific.
The patent granted in Japan is part of Cereno’s third patent family associated with drug candidate CS1 and is titled “Delayed release pharmaceutical formulations comprising valproic acid and uses thereof”. It has been given patent number JP6975368 and will be valid through 2037, with the possibility of a patent extension of additional five years maximum.
Drug candidate CS1 is currently undergoing a Phase II study for the rare disease pulmonary arterial hypertension (PAH) following investigational new drug (IND) acceptance from US FDA in September 2021. The aim of the study is to confirm CS1’s safety, tolerability and efficacy in patients with PAH. It will be conducted at up to nine different clinical centers in USA with 30 participating patients.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.